Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity and directed against PD-1.Camrelizumab binds PD-1 with a binding affinity of up to 3 nM and is inhibitory to PD-1/PD-L1 with an IC50 of 0.70 nM.Camrelizumab exhibits anti-tumor activity and is well tolerated in the study cancers including NSC-LC, ESCC, Hodgkin's lymphoma and advanced HCC.